'john.mattio@hcinternational.net' onClick="var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='93917079';s.tl(this,'o','ExternalLink');">john.mattio@hcinternational.net
Web:
http://www.hcinternational.net
BIOSTAR PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
March 31, December 31,
2010 2009
(Unaudited) (Audited)
ASSETS
Current Assets
Cash and cash equivalents $8,642,418 $8,577,704
Accounts receivable 20,837,401 19,803,434
Inventories 564,955 340,078
Prepaid expenses and other receivables 1,487,143 1,500,327
Total Current Assets 31,531,917 30,221,543
Deposits 877,693 1,316,328
Property, plant and equipment, net 5,202,236 4,340,917
Intangible assets, net 11,314,977 11,131,681
Total Assets $48,926,823 $47,010,469
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued expenses $4,005,676 $3,559,281
Value-added tax payable 628,908 1,050,051
Income tax payable 920,079 1,481,266
Total Current Liabilities 5,554,663 6,090,598
Commitment and contingencies
Stockholders' Equity
Series B, convertible preferred
stock, $0.001 par value, 5,000,000 shares
authorized, 1,467,317 and 3
'/>"/>SOURCE Biostar Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1.
Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai2.
Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results3.
Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT4.
Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program5.
Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 20096.
Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 20087.
Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities8.
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.9.
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 200910.
Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors 11.
Lotus Pharmaceuticals, Inc. Appoints OTC Division Head